Premium
Human Monoclonal Antibodies to Pseudomonas aeruginosa Produced by EBV‐Transformed Cells
Author(s) -
Suzuki Hidenori,
Okubo Yuichi,
Moriyama Mayumi,
Sasaki Manami,
Matsumoto Yoshiko,
Hozumi Toyoharu
Publication year - 1987
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1987.tb01328.x
Subject(s) - monoclonal antibody , biology , pseudomonas aeruginosa , antibody , microbiology and biotechnology , transformation (genetics) , monoclonal , epstein–barr virus , virology , virus , immunoglobulin m , immunoglobulin g , immunology , bacteria , gene , genetics
Numerous lymphoblastoid cell lines (LCLs) which secreted antibodies against Pseudomonas aeruginosa (all Fisher's immunotypes and Homma's immunotype 1) were established by Epstein‐Barr virus (EBV)‐transformation of lymphocytes. Five LCLs were established as long‐term culture lines and their properties were determined. These LCLs produced monoclonal antibodies to Fisher's immunotype 1 and 4 and Homma's immunotype 1, and their immunoglobulin classes were IgM, IgG, and IgA. We found that three monoclonal antibodies (G3‐1, H7‐2, and E10‐1) among them successfully protected mice from the corresponding immunotype of P. aeruginosa infection. Their protective dose (PD 50 ) values were 0.5, 2.6, and 3.1 μ g immunoglobulin/mouse. These human monoclonal antibodies against P. aeruginosa prepared by EBV‐transformation method will be a valuable aid for the treatment for severe P. aeruginosa infections.